Kestra Medical Technologies Ltd. Common Stock (KMTS)
Stock · NASDAQ · Health Care
$27.16as of 10/16/2026
Price chart
Active signals
KMTS Signal Track Record
How signals performed across all stocks →What KMTS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 6 | +17.2% | 83% | September 9, 2026 |
| Volume Spike | 5 | -13.6% | 20% | September 14, 2026 |
| Bollinger Band Breakout | 4 | -11.3% | 0% | September 25, 2026 |
| 200-Day Moving Average TouchActive now | 4 | +2.9% | 50% | September 10, 2026 |
| Any 20-session window (baseline) | -1.8% | 48% |
Computed by MarketWall from daily closing prices since December 18, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About KMTS
Kestra Medical Technologies, Ltd. operates as a wearable medical device and digital healthcare company. It focuses on transforming patient outcomes in cardiovascular disease through connected monitoring, therapeutic intervention, and data-driven clinical insights. The company also develops and commercializes Cardiac Recovery System platform, an integrated cardiac recovery ecosystem designed to support patients at ele…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 443
Fundamentals
- 1-day range
- $25.66$28.78
- Market cap
- $1.48B
- P/E (trailing)
- —
- P/E (forward)
- -13.96
- EPS (trailing)
- $-2.67
- Dividend yield
- —
- Beta
- 1.51
- Avg. volume
- 337.3K
How Kestra Medical Technologies Ltd. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Jul 14, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Kestra Medical Technologies Ltd. Common Stock Competitors
Chosen by industry and closest market cap.
- KMTSKestra Medical Technologies Ltd. Common Stock$27.24▼ 5.02%Market cap $1.48BP/E —$17.34$30
- ATECAlphatec Holdings Inc. Common Stock$10.46▼ 4.30%Market cap $1.42BP/E —$6.82$23.29
- IARTIntegra LifeSciences Holdings Corporation Common Stock$13.21▼ 2.37%Market cap $1.33BP/E —$8.7$20.49
- AORTArtivion Inc. Common Stock$21.78▼ 0.41%Market cap $1.29BP/E 117.64$19.16$48.25
- TNDMTandem Diabetes Care Inc. Common Stock$16.24▼ 1.69%Market cap $1.29BP/E —$12.26$29.65
- INSPInspire Medical Systems Inc. Common Stock$68.79▼ 1.90%Market cap $1.70BP/E 15.06$38.91$147.03
- BVSBioventus Inc. Class A Common Stock$13.3▼ 3.69%Market cap $1.17BP/E 21.32$6.46$15.89
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| KMTS Kestra Medical Technologies Ltd. Common Stock | $1.48B | — | $27.24 | ▼ 5.02% | $17.34$30 |
| ATEC Alphatec Holdings Inc. Common Stock | $1.42B | — | $10.46 | ▼ 4.30% | $6.82$23.29 |
| IART Integra LifeSciences Holdings Corporation Common Stock | $1.33B | — | $13.21 | ▼ 2.37% | $8.7$20.49 |
| AORT Artivion Inc. Common Stock | $1.29B | 117.64 | $21.78 | ▼ 0.41% | $19.16$48.25 |
| TNDM Tandem Diabetes Care Inc. Common Stock | $1.29B | — | $16.24 | ▼ 1.69% | $12.26$29.65 |
| INSP Inspire Medical Systems Inc. Common Stock | $1.70B | 15.06 | $68.79 | ▼ 1.90% | $38.91$147.03 |
| BVS Bioventus Inc. Class A Common Stock | $1.17B | 21.32 | $13.3 | ▼ 3.69% | $6.46$15.89 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Kestra Medical Technologies Earns Five-Star Rating on Newsweek’s List of America’s Greatest Mid-Market CompaniesYahoo · 10/1/2026
- Kestra Medical Technologies (KMTS) Could Be 17% Undervalued Following Raised Revenue OutlookYahoo · 9/22/2026
- Kestra Medical (KMTS) Raises Outlook. Can Better Reimbursement Support Scale?Yahoo · 9/17/2026
- Kestra Medical: Strong Scaling Story, But Profitability Still On The HorizonSeekingAlpha · 9/16/2026
- KESTRA MEDICAL TECHNOLOGIES, LTD. Q1 2027 Earnings Call SummaryYahoo · 9/15/2026
- Kestra Medical Technologies Posts Mixed Q1 Results, Joins Enova International, Dave and Buster's And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · 9/15/2026
- Kestra Medical Technologies Ltd (KMTS) (Q1 2027) Earnings Call Highlights: Revenue Jumps 60% as ...Yahoo · 9/15/2026
- BTIG Reiterates Buy on Kestra Medical Techs, Maintains $32 Price TargetBenzinga · 9/15/2026
Insider Activity
Insider Actions →- Raymond W. Cohen · September 30, 2026 · Sale3.3K @ $29.28
- Kwo Elizabeth · September 21, 2026 · Sale4.0K @ $24.26
- Hanley Conor · September 9, 2026 · Grant7.2K
- Reilly Kevin C · September 9, 2026 · Grant7.2K
- Kwo Elizabeth · September 9, 2026 · Grant7.2K
- Mary Kay Ladone · September 9, 2026 · Grant7.2K
- Schwartz Jeffrey Lawrence · September 9, 2026 · Grant7.2K
- Raymond W. Cohen · September 9, 2026 · Grant7.2K
- Hanley Conor · September 8, 2026 · Sale5.7K @ $25.25
- Reilly Kevin C · September 8, 2026 · Sale2.9K @ $25.13
- Mary Kay Ladone · September 8, 2026 · Sale3.9K @ $25.2
- Schwartz Jeffrey Lawrence · September 8, 2026 · Sale3.9K @ $25.18
- Webster Brian Daniel · August 17, 2026 · Sale15.0K @ $27.48
- Mahboob Vaseem · August 7, 2026 · Sale500 @ $26.33
- Mahboob Vaseem · August 7, 2026 · Sale25.8K @ $25.87
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 7, 2026
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target
BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.
Analyst Reiterates Rating on Kestra Medical Technologies with $32 Target. BTIG has reiterated its positive view on Kestra Medical Technologies, keeping a $32 price target on the stock. The reaffirmation comes as broader medical device peers report mixed quarterly results: Phreesia fell short of Q2 earnings and revenue estimates, while Medtronic beat on both lines. These peer results provide context for the medical device sector backdrop against which Kestra is being evaluated.